mometasone furoate + formoterol fumarate

Mometasone furoate + formoterol fumarate is a fixed-dose inhaled combination of mometasone furoate, an inhaled corticosteroid, and formoterol fumarate, a long-acting beta2-adrenergic agonist. Mometasone activates the glucocorticoid receptor to suppress airway inflammation, while formoterol activates beta2-adrenergic receptors on airway smooth muscle to provide rapid, sustained bronchodilation. It is supplied as a pressurized metered-dose inhalation aerosol and marketed for maintenance treatment of asthma, including in patients aged 5 years and older in the United States. Phase III COPD studies evaluated 200/10 micrograms and 400/10 micrograms twice daily, demonstrating improved lung function and reductions in exacerbations versus placebo or individual components, but the combination is not approved in the United States for COPD.

Brand names

DuleraZenhale

Other names

MF/Fmometasone furoate/formoterol fumaratemometasone furoate/formoterol fumarate dihydratemometasone/formoterol